Andreessen Horowitz and (a16z) Bio + Health led a $200m Series B round in Genesis Therapeutics.

Andreessen Horowitz and (a16z) Bio + Health led a $200m Series B round in Genesis Therapeutics, a researcher of AI and biotech to accelerate the discovery of new medicines, with participation from Fidelity Management & Research Company, BlackRock, NVentures, T. Rowe Price Associates, Rock Springs Capital, Radical Ventures, and Menlo Ventures. “AI presents a potent opportunity to revolutionize the drug discovery process, which frequently struggles to produce viable drug candidates against targets that are biologically well-validated but considered undruggable due to highly challenging chemistry. This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic. The addition of our new lead investor, and other meaningful additions to our biotech and AI-oriented syndicate, will support Genesis in developing breakthrough therapies for patients with severe unmet medical needs, and their families, capitalizing on the broad applicability and potential of the GEMS AI platform,” Evan Feinberg, Genesis CEO.